

Finnish growth company Mendor starts collaboration with a global pharma corporation to develop diabetes treatment

Medical device growth company Mendor has started a local collaboration in Finland with the pharma company Novartis Finland Oy. Novartis Finland is a part of the international Novartis corporation, one of the world's leading pharmaceutical companies.

Mendor and Novartis have started a pilot project in Finland that aims to develop the treatment of type 2 diabetes in a more tailored direction. "The treatment should also be individual, as is the behavior of blood glucose", says Mendor's medical director, endocrinologist Antti Virkamäki.

Twelve clinics and 500 Finnish patients with type 2 diabetes take part in the project. All patients get common directions to time the blood glucose measurements, based on their individual daily routines. The medical staff then gets a description, how the blood glucose behaves, and can weigh the different treatment options.

Founded in 2005 in Helsinki, Finland, Mendor designs, develops and markets innovative diabetes care products. Mendor's first product, blood glucose meter named the Discreet™, has received high praise from clinicians and diabetologists all over the world. The meter contains all the necessary components for daily blood glucose measurements: meter, strips and lancing device in an integrated, all-in-one device the size of a cell phone. Mendor Discreet™ is designed to simplify the lives of people with diabetes who regularly need to test their blood glucose levels.

With Discreet™ you get a license for Balance™, an advanced internet based self-care application. Balance™ empowers the diabetic to see a full picture of the treatment's status, and possible improvement targets. The medical staff gets a solid platform for discussion with the patient.

Images available on request. For more information, visit: www.mendor.com

Media Contact:

Kristian Ranta - CEO, Co-Founder

Mobile: +358 45 673 3313

E-mail: kristian.ranta@mendor.com